In light of these observations and in order to determine if SMAD7 is a viable target for EE therapy, our aim in the present study was to characterize TGF-β and SMAD protein expression in EE patients, comparing these data to expression levels in both healthy controls and patients with CD. This evidence concerns the gene TGFB1 and ethylmalonic encephalopathy.